LRD, ISL, QCZ, JLW, JET, DJP, and DG collected and analyzed data and revised the manuscript
Chang, M
I am delighted to see that these data reveal that the glucagon/GLP-1 dual agonism of survodutide offers a promising approach for people with obesity, and for those with obesity-associated metabolic liver diseases including MASLD and MASH. Obesity is a complex disease linked to how the body manages metabolism
Some of the most common or potential side effects include: Nausea Constipation Vomiting Diarrhea Abdominal Pain Headache Indigestion Injection site reactions Dizziness Back pain Increased Lipase or Amylase Altered taste Nasopharyngitis (common cold) Passing Gas Bloating Belching Gastroenteritis Decreased appetite Fatigue Gastroesophageal reflux disease Low blood sugar (hypoglycemia) in those with Type 2 diabetes Upset stomach These symptoms often subside as your body adjusts to the medications
For detailed escalation charts, the tirzepatide dosing for weight loss in units guide provides exact unit conversions at every dose level
Aoyagi T, Aoyama T, Kojima F, Matsuda N, Maruyama M, Hamada M et al